Format

Send to

Choose Destination
Curr Opin Immunol. 2016 Jun;40:24-35. doi: 10.1016/j.coi.2016.02.006. Epub 2016 Mar 8.

Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection.

Author information

1
Biomunex Pharmaceuticals, 75116 Paris, France. Electronic address: ezhukovsky@biomunex.com.
2
Morse Consulting, 75016 Paris, France.
3
Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02129, United States. Electronic address: mvmaus@mgh.harvard.edu.

Abstract

To realize the full potential of cancer immunotherapy, the latest generation immunotherapeutics are designed to harness the potent tumor-killing capacity of T cells. Thus, to mobilize T cells, new optimized bispecific antibody (BsAb) designs, enabling efficient polyclonal redirection of cytotoxic activity through binding to CD3 and a Tumor Associated Antigen (TAA) and refined genetically modified T cells have recently expanded the arsenal of available options for cancer treatment. This review presents the current understanding of the parameters crucial to the design of optimal T cell redirecting BsAb and chimeric antigen receptor (CAR)-modified T cells. However, there are additional questions that require thorough elucidation. Both modalities will benefit from design changes that may increase the therapeutic window. One such approach could employ the discrimination afforded by multiple TAA to significantly increase selectivity.

PMID:
26963133
PMCID:
PMC4884546
DOI:
10.1016/j.coi.2016.02.006
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center